What is HBeAg negative hepatitis B?
Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) occurs at the late phase in hepatitis B virus (HBV) infection’s natural history. The disease is characterized by progressive liver damage due to variants with mutations in the precore/core promoter region that reduce or abolish HBeAg expression.
What is the treatment for HBeAg negative?
The most common antiviral treatments are either entecavir (Baraclude) or tenofovir (Viread). These two are considered the most powerful at quickly reducing viral load (HBV DNA) and have a very low risk of causing drug resistance, which is critical considering the long-term treatment required by HBeAg-negative patients.
Is HBV negative good?
Normal results are negative or nonreactive, meaning that no hepatitis B surface antigen was found. If your test is positive or reactive, it may mean you are actively infected with HBV. In most cases this means that you will recover within 6 months.
What is HBeAg nonreactive?
A non-reactive HBeAg result (with a reactive anti-HBe result) in a person with hepatitis B indicates that the infection is in its initial phase, before peak replication of the virus. If the anti-HBe is reactive, it may indicate that viral replication is now very low.
Is HBeAg negative good?
A negative HBeAg result indicates very minimal or no HBV replication. Positive anti-HBe results usually indicate inactivity of the virus and low infectivity. Positive anti-HBe results in the presence of detectable HBV DNA in serum also indicate active viral replication in these patients.
How long people who were HBeAg negative when they started antivirals should remain on treatment?
EASL guidelines say non-cirrhotic, HBeAg-negative patients who have had at least three years of antiviral treatment, undetectable viral load and no signs of liver damage can stop treatment, as long as there is frequent follow-up monitoring.
What does HBeAg positive mean?
The hepatitis e antigen, or HBeAg, is a marker of an actively replicating HBV virus infection. Those with a positive HBeAg have active replication in their liver cells, more of the virus circulating in their blood, and as a result, they are more infectious, with a higher likelihood of transmitting HBV to others.
What is the latest treatment for hepatitis B?
VIR-2218 is an investigational GalNAc-conjugated small interfering ribonucleic acid (siRNA) therapeutic in development for functional cure of chronic hepatitis B virus infection (CHB). VIR-2218 was created using Enhanced Stabilization Chemistry Plus, which retains in vivo potency while reducing off-target effects.
